James P Franciosi1, Edward B Mougey2, Andre Williams3, Roberto A Gomez Suarez4, Cameron Thomas5, Christa L Creech6, Katherine George7, Diana Corao8, John J Lima2. 1. Division of Gastroenterology, Hepatology and Nutrition, Nemours Children's Hospital, 13535 Nemours Parkway, Orlando, FL, 32827, USA. james.franciosi@nemours.org. 2. Center for Pharmacogenomics and Translational Research, Nemours Children's Health System, Jacksonville, FL, USA. 3. Center for Health Care Delivery Science, Nemours Children's Health System, Jacksonville, FL, USA. 4. Division of Gastroenterology, Hepatology and Nutrition, Nemours Children's Hospital, 13535 Nemours Parkway, Orlando, FL, 32827, USA. 5. St. Jude Children's Research Hospital, Tampa, FL, USA. 6. Intermountain Medical Center, Murray, UT, USA. 7. Nova Southeastern University, Fort Lauderdale, FL, USA. 8. Department of Pathology, A.I. DuPont Hospital for Children, Wilmington, DE, USA.
Abstract
When pediatric gastroesophageal reflux disease (GERD) that is refractory to proton pump inhibitor (PPI) medication treatment is identified in clinical practice and anti-reflux surgery (ARS) is being considered, genetic factors related to PPI metabolism by the CYP2C19 enzyme are currently not part of the clinical decision-making process. Our objective was to test the hypothesis that the distribution of the extensive metabolizer (EM) phenotypes among children undergoing ARS after failing PPI therapy would differ compared to controls (children with no history of ARS). We conducted a case-control study between children across the Nemours Health System from 2000 to 2014 who received ARS after failing PPI therapy and a control group comprised of healthy children. Our results demonstrated 2.9% of ARSs vs 20.8% of controls were poor metabolizers (PMs), 55.9% of ARSs vs 49.0% of controls were normal metabolizers (NMs), and 41.2% of ARSs vs 30.2% of controls were EMs; p = 0.035. Next, we performed a multiple-regression model to account for race as a potential confounding variable and the EM group was significantly associated with ARS compared to controls (OR 9.78, CI 1.25-76.55, p < 0.03). CONCLUSION: Among children with medically refractory GERD despite PPI therapy, carriage of CYP2C19*17 allele corresponding to the EM phenotype was associated with ARS. Prospective comparative personalized medicine effectiveness studies are needed to determine if CYP2C19 genotype-guided dosing improves response to PPI therapy without a corresponding increase in adverse effects in children. What is known: • Anti-reflux surgery (ARS) is one of the most common surgical procedures performed in children for the indication of refractory gastroesophageal reflux disease (GERD). What is new: • Individualizing PPI medication dosing based on CYP2C19 diplotype may avoid GERD treatment failures and reduce the need for anti-reflux surgery (ARS).
When pediatric gastroesophageal reflux disease (GERD) that is refractory to proton pump inhibitor (PPI) medication treatment is identified in clinical practice and anti-reflux surgery (ARS) is being considered, genetic factors related to PPI metabolism by the CYP2C19 enzyme are currently not part of the clinical decision-making process. Our objective was to test the hypothesis that the distribution of the extensive metabolizer (EM) phenotypes among children undergoing ARS after failing PPI therapy would differ compared to controls (children with no history of ARS). We conducted a case-control study between children across the Nemours Health System from 2000 to 2014 who received ARS after failing PPI therapy and a control group comprised of healthy children. Our results demonstrated 2.9% of ARSs vs 20.8% of controls were poor metabolizers (PMs), 55.9% of ARSs vs 49.0% of controls were normal metabolizers (NMs), and 41.2% of ARSs vs 30.2% of controls were EMs; p = 0.035. Next, we performed a multiple-regression model to account for race as a potential confounding variable and the EM group was significantly associated with ARS compared to controls (OR 9.78, CI 1.25-76.55, p < 0.03). CONCLUSION: Among children with medically refractory GERD despite PPI therapy, carriage of CYP2C19*17 allele corresponding to the EM phenotype was associated with ARS. Prospective comparative personalized medicine effectiveness studies are needed to determine if CYP2C19 genotype-guided dosing improves response to PPI therapy without a corresponding increase in adverse effects in children. What is known: • Anti-reflux surgery (ARS) is one of the most common surgical procedures performed in children for the indication of refractory gastroesophageal reflux disease (GERD). What is new: • Individualizing PPI medication dosing based on CYP2C19 diplotype may avoid GERD treatment failures and reduce the need for anti-reflux surgery (ARS).
Authors: Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg Journal: Clin Pharmacol Ther Date: 2006-01 Impact factor: 6.875
Authors: T Furuta; N Shirai; M Takashima; F Xiao; H Hanai; H Sugimura; K Ohashi; T Ishizaki; E Kaneko Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875
Authors: Barbara Gawrońska-Szklarz; Joanna Wrześniewska; Teresa Starzyńska; Andrzej Pawlik; Krzysztof Safranow; Katarzyna Ferenc; Marek Droździk Journal: Eur J Clin Pharmacol Date: 2005-06-23 Impact factor: 2.953
Authors: Christiana J Bernal; Ida Aka; Robert J Carroll; Joseph R Coco; John J Lima; Sari A Acra; Dan M Roden; Sara L Van Driest Journal: Pediatrics Date: 2019-11-07 Impact factor: 7.124
Authors: Ping Siu Kee; Simran D S Maggo; Martin A Kennedy; Murray L Barclay; Allison L Miller; Klaus Lehnert; Maurice A Curtis; Richard L M Faull; Remai Parker; Paul K L Chin Journal: Front Genet Date: 2022-05-19 Impact factor: 4.772
Authors: Monica Tang; Kathryn V Blake; John J Lima; Edward B Mougey; James Franciosi; Stephan Schmidt; Md Jobayer Hossain; Marjan Cobbaert; Bernard M Fischer; Jason E Lang Journal: Contemp Clin Trials Date: 2019-01-16 Impact factor: 2.226
Authors: John J Lima; Cameron D Thomas; Julia Barbarino; Zeruesenay Desta; Sara L Van Driest; Nihal El Rouby; Julie A Johnson; Larisa H Cavallari; Valentina Shakhnovich; David L Thacker; Stuart A Scott; Matthias Schwab; Chakradhara Rao S Uppugunduri; Christine M Formea; James P Franciosi; Katrin Sangkuhl; Andrea Gaedigk; Teri E Klein; Roseann S Gammal; Takahisa Furuta Journal: Clin Pharmacol Ther Date: 2020-09-20 Impact factor: 6.903
Authors: Emily J Cicali; Kathryn Blake; Yan Gong; Edward B Mougey; Hadeel Al-Atrash; Nancy Chambers; Jolanda Denham; Jonathan Evans; Donald E George; Roberto Gomez; Pablo Palomo; Salik Taufiq; Julie A Johnson; John J Lima; James P Franciosi Journal: Clin Transl Sci Date: 2018-10-20 Impact factor: 4.689
Authors: Edward B Mougey; Andre Williams; Ashlan J Kunz Coyne; Carolina Gutiérrez-Junquera; Sonia Fernández-Fernández; Maria Luz Cilleruelo; Ana Rayo; Luis Echeverría; Enriqueta Román; Carmen González Lois; Montserrat Chao; Hadeel Al-Atrash; John J Lima; James P Franciosi Journal: J Pediatr Gastroenterol Nutr Date: 2019-11 Impact factor: 2.839